Skip Navigation

European Heart Journal 2002 23(6):444-457; doi:10.1053/euhj.2001.2751
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leebeek, F.W.G.
Right arrow Articles by Simoons, M.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leebeek, F.W.G.
Right arrow Articles by Simoons, M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable

F.W.G. Leebeeka, E. Boersmab, C.P. Cannonc, F.J.J. van de Werfd and M.L. Simoonsb

a Department of Hematology, Erasmus University Medical Center Rotterdam, The Netherlands
b Thoraxcentrum, Department of Cardiology, Erasmus University Medical Center Rotterdam, The Netherlands
c Harvard Medical School, Brigham and Women's Hospital, Boston, U.S.A.
d Catholic University Leuven, Belgium

Received March 26, 2001; accepted April 21, 2001

References

  1. Br Med J (Clin Res Ed). 1988;30:320–331
  2. BMJ. 1994;308:81–106[Abstract/Free Full Text]
  3. Lancet. 1996;348:1329–1339[CrossRef][Web of Science][Medline]
  4. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147–152[Abstract]
  5. Lancet. 1994;343:499–503[Web of Science][Medline]
  6. Ronner E, Dykun Y, van den Brand MJ, van der Wieken LR, Simoons ML. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J. 1998;19:1608–1616[Free Full Text]
  7. Kong DF, Califf RM, Miller DP. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin ischemic heart disease. Circulation. 1998;98:2829–2835[Abstract/Free Full Text]
  8. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  9. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  10. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  11. Lancet. 1998;352:87–92[Web of Science][Medline]
  12. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  13. Lancet. 1997;349:1422–1428[CrossRef][Web of Science][Medline]
  14. Tcheng, JE, The ESPRIT study: a randomized, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation
  15. Brener SJ, Barr LA, Burchenal JE. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734–741[Abstract/Free Full Text]
  16. Neumann FJ, Kastrati A, Schmitt C. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915–921[Abstract/Free Full Text]
  17. N Engl J Med. 1998;339:436–443[Abstract/Free Full Text]
  18. Topol EJ. do Tirofiban and Rheopro give similar efficacy trial. Circulation. 2000;:
  19. N Engl J Med. 1998;338:1498–1505[Abstract/Free Full Text]
  20. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  21. Circulation. 1998;97:2386–2395[Abstract/Free Full Text]
  22. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048[Abstract/Free Full Text]
  23. O’Shea JC, Hafley GE, Greenberg S. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT Trial: a randomized controlled trial. JAMA. 2001;285:2468–2473[Abstract/Free Full Text]
  24. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227–231[CrossRef][Web of Science][Medline]
  25. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation. 2000;101:E76–E80
  26. O'Neill WW, Serruys P, Knudtson M. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med. 2000;342:1316–1324[Abstract/Free Full Text]
  27. Cannon CP, McCabe CH, Wilcox RG. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149–156[Abstract/Free Full Text]
  28. Lancet. 2000;355:337–345[CrossRef][Web of Science][Medline]
  29. Newby LK. A randomized comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes (ACS): results of the second SYMPHONY trial. Kleiman NS, Califf RM. Results from Late-Breaking Clinical Trial Sessions at ACCIS 2000 and ACC 2000. 2000. p. 309–325
  30. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989;80:1766–1774[Abstract/Free Full Text]
  31. Steinbuhl SR, Kottke-Marchant K, Moliterno DJ. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999;100:1977–1982[Abstract/Free Full Text]
  32. Harrington RA, Armstrong PW, Graffagnino C. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation. 2000;102:728–735[Abstract/Free Full Text]
  33. Akkerhuis KM, Neuhaus KL, Wilcox RG. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation: a phase II study. Eur Heart J. 2000;21:2042–2055[Abstract/Free Full Text]
  34. Cannon CP, McCabe CH, Borzak S. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998;97:340–349[Abstract/Free Full Text]
  35. Kereiakes DJ, Kleiman NS, Ferguson JJ. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 1998;98:1268–1278[Abstract/Free Full Text]
  36. Giugliano RP, McCabe CH, Sequiera RF. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000;140:81–93[CrossRef][Web of Science][Medline]
  37. Peter K, Schwarz M, Ylanne J. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa inhibitors. Blood. 1998;92:3240–3249[Abstract/Free Full Text]
  38. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orobifiban in Patients with Unstable coronary syndromes. Thrombolysis in Myocardial Infarction. Am J Cardiol. 2000;85:491–493[CrossRef][Web of Science][Medline]
  39. Cox D, Smith R, Quinn M. Evidence of platelet activation during treatment with a GPIIa/IIIb antagonist in patients presenting acute coronary syndromes. J Am Coll Cardiol. 2000;36:1514–1519[Abstract/Free Full Text]
  40. Pratico D, Murphy NP, Fitzgerald DJ. Interaction of a thrombin inhibitor and a platelet GPIIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther. 1997;281:1178–1185[Abstract/Free Full Text]
  41. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘clinical restenosis’. J Clin Invest. 1996;98:863–874[Web of Science][Medline]
  42. Dangas G, Marmur JD, King TE. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J. 1999;138:49–54[CrossRef][Web of Science][Medline]
  43. Phillips DR, Teng W, Arfsten A. Effect of Ca2+ on GPIIb-IIIa interactions with integrilin: enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488–1494[Abstract/Free Full Text]
  44. Rebello SS, Huang J, Faul JD, Lucchesi BR. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. J Thromb Thrombolysis. 2000;9:23–28[CrossRef][Web of Science][Medline]
  45. Harrington RA, Kleiman NS, Granger CB, Ohman EM, Berkowitz SD. Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J. 1998;136:S43–S50[CrossRef][Web of Science][Medline]
  46. Coller BS, Land D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIB/IIIa receptor blockade. Circulation. 1997;95:860–867[Abstract/Free Full Text]
  47. Smith JW, Steinhubl SR, Lincoff AM. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620–625[Abstract/Free Full Text]
  48. Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost. 1999;82:1307–1311[Web of Science][Medline]
  49. Weiss EJ, Bray PF, Tayback M. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090–1094[Abstract/Free Full Text]
  50. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet. 1997;349:385–388[CrossRef][Web of Science][Medline]
  51. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350:1217–1219[CrossRef][Web of Science][Medline]
  52. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201–206[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 234S - 264S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. L. Simoons, I. W. G. Bobbink, J. Boland, M. Gardien, P. Klootwijk, A. W. A. Lensing, W. Ruzyllo, V. A. W. M. Umans, A. Vahanian, F. Van De Werf, et al.
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2183 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons, et al.
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial
Circulation, January 28, 2003; 107(3): 437 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
Eur. Heart J., January 1, 2003; 24(1): 77 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840.
[Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leebeek, F.W.G.
Right arrow Articles by Simoons, M.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leebeek, F.W.G.
Right arrow Articles by Simoons, M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?